Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 37,841 | 36,383 | 63,542 | 39,933 | 85,388 |
| Marketable Securities | 210,953 | 194,310 | 236,768 | 297,218 | 284,522 |
| Receivables | 38,645 | 40,631 | 39,787 | 39,907 | 39,618 |
| TOTAL | $299,852 | $286,584 | $351,029 | $390,303 | $422,791 |
| Non-Current Assets | |||||
| PPE Net | 32,688 | 25,051 | 15,479 | 12,119 | 11,919 |
| Investments And Advances | 0 | 42,510 | 0 | 0 | 0 |
| Other Non-Current Assets | 44,112 | 44,676 | 47,049 | 26,077 | 27,565 |
| TOTAL | $76,800 | $112,237 | $62,528 | $38,196 | $39,484 |
| Total Assets | $376,652 | $398,821 | $413,557 | $428,499 | $462,275 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,002 | 10,675 | 6,726 | 9,326 | 4,097 |
| Accrued Expenses | 13,547 | 12,830 | 10,630 | 11,603 | 18,339 |
| Other current liabilities | 34,462 | 32,295 | 33,671 | 36,512 | 35,076 |
| TOTAL | $57,535 | $58,231 | $54,608 | $62,407 | $62,787 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 190,303 | 191,675 | 192,835 | 174,208 | 182,753 |
| TOTAL | $190,303 | $191,675 | $192,835 | $174,208 | $182,753 |
| Total Liabilities | $247,838 | $249,906 | $247,443 | $236,615 | $245,540 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 21,194 | 21,189 | 21,179 | 21,156 | 21,059 |
| Common Shares | 212 | 212 | 212 | 212 | 211 |
| Retained earnings | -323,040 | -294,217 | -271,559 | -240,402 | -206,995 |
| Other shareholders' equity | 302 | -653 | -667 | -534 | -1,174 |
| TOTAL | $128,814 | $148,915 | $166,114 | $191,884 | $216,735 |
| Total Liabilities And Equity | $376,652 | $398,821 | $413,557 | $428,499 | $462,275 |